SCHEMBL20122738

SCHEMBL20122738

COc1ccc(-c2cc(Cl)cc3c4ccncc4n(CC4(C)COC4)c23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 4/20 0.49
HASPIN Q8TF76 1/20 0.38
PIK3CD O00329 2/20 0.37
PRKDC P78527 1/20 0.37
CHUK O15111 1/20 0.34
ICOSLG O75144 1/20 0.34
ICOS Q9Y6W8 1/20 0.34
GSK3B P49841 2/20 0.33
DYRK3 O43781 1/20 0.33
CLK1 P49759 1/20 0.33
CLK2 P49760 1/20 0.33
CLK3 P49761 1/20 0.33
DYRK2 Q92630 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
DYRK4 Q9NR20 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
GCGR P47871 1/20 0.33
MAPK14 Q16539 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664344 0.83 HASPIN (0.44) DYRK1AHASPINPIK3CDPRKDCCHUK
SCHEMBL20122793 0.83 HASPIN (0.44) DYRK1AHASPINPIK3CDPRKDCCHUK
SCHEMBL20122845 0.81 DYRK1A (0.47) DYRK1AHASPINPIK3CDCHUKICOSLG
SCHEMBL30664129 0.81 DYRK1A (0.47) DYRK1AHASPINPIK3CDCHUKICOSLG
SCHEMBL20122707 0.80 DYRK1A (0.46) DYRK1AHASPINCHUK
SCHEMBL20123071 0.75 CYP11B1 (0.41) DYRK1AHASPINPIK3CDPRKDCCHUK
SCHEMBL30664146 0.75 CYP11B1 (0.41) DYRK1AHASPINPIK3CDPRKDCCHUK
SCHEMBL20123010 0.73 ROCK2 (0.40) DYRK1AGSK3BNFATC1
SCHEMBL30664221 0.73 ROCK2 (0.40) DYRK1AGSK3BNFATC1
SCHEMBL20123022 0.73 MGAT2 (0.47) DYRK1AHASPINGCGRMAPK14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885HASPIN 2412/4885PIK3CD 1573/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885HASPIN 2412/4885PIK3CD 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.